Fubon Insurance’s FY2023 underwriting results still weighed down by Covid claims
March 25 2024 by Georgina Lee
-
New Zealand central bank warns Quest Insurance over non-compliance
- November 12
Quest has acknowledged and remedied the breaches of its obligations and is in the process of implementing further risk management measure, RBNZ said.
-
NZ non-life segment growth to remain robust even as carriers adjust rates: AM Best
- November 11
In its latest report on the segment, the rating agency has maintained a stable outlook citing solid premium growth supported by rate adjustments.
-
Japanese watchdog fines non-life insurers US$13m for price fixing
- November 1
The report highlighted the summary of violations of antitrust rules by Mitsui Sumitomo, Sompo Japan , Aioi Nissay Dowa and Tokio Marine & Nichido Fire.
-
APAC reinsurers prioritise profit amid slower premium growth: AM Best
- November 1
Asian reinsurers have restructured their retro programs, leading to adjustments in cat capacity and a reduction in cat exposure accumulation, says AM Best’s Christie Lee.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
